ReviewAnnals of the rheumatic diseases2004
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
Review in Annals of the rheumatic diseases, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 56 citations in OpenAlex.
- Rheumatoid Arthritis Has Won the Battle but Not the War: How Many Joints Will We Save Tomorrow?Medicina (Kaunas, Lithuania) · 2023Review
- The thromboembolic risk in giant cell arteritis: a critical review of the literature.International journal of rheumatology · 2014Review
- Perspectives on the use of gene therapy for chronic joint diseases.Current gene therapy · 2008Review
- The effect of covalently immobilized rhIL-1ra-ELP fusion protein on the inflammatory profile of LPS-stimulated human monocytes.Biomaterials · 2007Article
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Annals of the rheumatic diseases · 2006Article
- Bacterial meningitis associated with infliximab.Pharmacy world & science : PWS · 2006Article
- Treatment of rheumatoid arthritis.BMJ (Clinical research ed.) · 2006Review
- Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.Annals of the rheumatic diseases · 2005Review
- Update of TNF-alpha antagonists and cardiovascular disease in rheumatoid arthritis.Current rheumatology reports · 2005Review
- TNF-blocking therapy in rheumatoid arthritis and ankylosing spondylitis: why is cost-effectiveness a major issue?Current rheumatology reports · 2005Review
- [Rheumatology].Der Internist · 2005Review
- Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies.BMJ (Clinical research ed.) · 2005Review
- [Position on choice of agents among TNF inhibitors].Zeitschrift fur Rheumatologie · 2005Article
- Psoriatic arthritis treatment: biological response modifiers.Annals of the rheumatic diseases · 2005Review
- Review
- Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis?Arthritis research & therapy · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.